... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products:(Date:12/4/2008)... Boston, MA (PRWEB) Decembe... not be as funny as David Letterman,s nightly coun... long-term health. Here are this year,s winners, c... Letter:, , , , ,1. Blood sugar: How low should i...ugar levels is probably not the best approach to t...
(Date:12/4/2008)...s for PE Classrooms Released , , CORPUS CHR...hundreds of physical educators at the annual Texas...e (TAHPERD) conference, Source Brands, Inc., maker...ly released the first "active gaming" lesson plans... is entitled GameCoach(TM) and is available nati...
(Date:12/4/2008)...ication used for high blood pressure does not impr...ew results from a large, international study. , ...est University Baptist Medical Center in key leade...he New England Journal of Medicine , published to...hers, who continue to study other medications in s...
(Date:12/4/2008)...wswire/ -- The American Academy of,Dermatology (A...tamin D,drawing on the scientific literature to ...n adequate amount of this vitamin. The Academy re...tritional sources and dietary supplements, and,no...diation from the sun or,indoor tanning devices, a...
Breaking Medicine News(10 mins):Health News:The Top 10 Health Stories of 2008, from the Harvard Health Letter 2Health News:The Top 10 Health Stories of 2008, from the Harvard Health Letter 3Health News:The Top 10 Health Stories of 2008, from the Harvard Health Letter 4Health News:GameCoach(TM) Combines High Tech With Old School PE School Equipment 2Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:American Academy of Dermatology Issues Position Statement on Vitamin D 2(Date:12/3/2008)...if., Dec. 3 Isis Pharmac...that OncoGenex Pharmaceuticals, Inc.,provided pos...linical trial of,OGX-011 in combination with doce... to docetaxel and prednisone alone ("the control a...ate resistant prostate cancer. The current 10.6,...
(Date:12/3/2008)...c. 3 Vical Incorporated,...inding letter of intent with EIP,Eczacibasi Ilac ...e company,s,Allovectin-7(R) immunotherapeutic pro... of Northern Cyprus. EIP has agreed to obtain the ...and to pay Vical upfront and milestone payments,p...
(Date:12/2/2008)... 3 Breast-specific gamm... cancers not found on mammograms or by,clinical e...nnual meeting of,the Radiological Society of Nort...most difficult to detect breast cancer-invasive,l..., M.D., professor of,radiology and director of th...
(Date:12/2/2008)... Dec. 2 IBT Laboratories, a leadin...boratory specializing in immunology and allergy as... evaluate the response of patients whose immune s...eficiency disorder, chemotherapy drugs, or because...nt rejection of a transplant. The company launched...
Breaking Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Schedules Revised for Flu Meningitis Vaccines 9466 1Schedules Revised for Flu Meningitis Vaccines 9466 2Time Critical Diagnosis Task Force Convenes in Jefferson City 9465 1Time Critical Diagnosis Task Force Convenes in Jefferson City 9465 2Manufacturing Organizations Identify Efficiencies in Maintenance Functions 9463 1Manufacturing Organizations Identify Efficiencies in Maintenance Functions 9463 2PCMA 3A New Study on Independent Pharmacy Reimbursements Will Raise Eyebrows on Capitol Hill 9461 1PCMA 3A New Study on Independent Pharmacy Reimbursements Will Raise Eyebrows on Capitol Hill 9461 2... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gi...results of two long-term studies,evaluating ambris...gonist (ERA) for the treatment of patients with pu...rm data are from patients,who originally participa... AMB-222, a Phase II study of patients who had,pre...
... Relationship Between Ability to Function and Trea...died, INDIANAPOLIS, May 21, 2007 /PRNewswire-First...ed anxiety disorder (GAD),treated with Cymbalta(R)...perform everyday activities at home, work and in s...rovements in global,functioning were the result of...
Other Medicine Technology:Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 2Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 3Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 4Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 5Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 6Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6